S&P 500   3,916.23 (-4.22%)
DOW   31,419.51 (-3.78%)
QQQ   291.13 (-4.91%)
AAPL   140.68 (-5.74%)
MSFT   254.63 (-4.57%)
FB   193.11 (-4.69%)
GOOGL   2,255.52 (-3.17%)
AMZN   2,133.04 (-7.56%)
TSLA   706.71 (-7.21%)
NVDA   169.21 (-6.91%)
BABA   87.26 (-5.14%)
NIO   15.71 (-5.53%)
AMD   96.02 (-6.29%)
CGC   5.60 (-4.92%)
MU   71.11 (-4.52%)
T   20.18 (-1.90%)
GE   75.23 (-1.53%)
F   12.75 (-5.76%)
DIS   104.39 (-3.91%)
AMC   12.72 (-1.40%)
PFE   50.28 (-2.06%)
PYPL   77.04 (-3.40%)
NFLX   177.26 (-6.98%)
S&P 500   3,916.23 (-4.22%)
DOW   31,419.51 (-3.78%)
QQQ   291.13 (-4.91%)
AAPL   140.68 (-5.74%)
MSFT   254.63 (-4.57%)
FB   193.11 (-4.69%)
GOOGL   2,255.52 (-3.17%)
AMZN   2,133.04 (-7.56%)
TSLA   706.71 (-7.21%)
NVDA   169.21 (-6.91%)
BABA   87.26 (-5.14%)
NIO   15.71 (-5.53%)
AMD   96.02 (-6.29%)
CGC   5.60 (-4.92%)
MU   71.11 (-4.52%)
T   20.18 (-1.90%)
GE   75.23 (-1.53%)
F   12.75 (-5.76%)
DIS   104.39 (-3.91%)
AMC   12.72 (-1.40%)
PFE   50.28 (-2.06%)
PYPL   77.04 (-3.40%)
NFLX   177.26 (-6.98%)
S&P 500   3,916.23 (-4.22%)
DOW   31,419.51 (-3.78%)
QQQ   291.13 (-4.91%)
AAPL   140.68 (-5.74%)
MSFT   254.63 (-4.57%)
FB   193.11 (-4.69%)
GOOGL   2,255.52 (-3.17%)
AMZN   2,133.04 (-7.56%)
TSLA   706.71 (-7.21%)
NVDA   169.21 (-6.91%)
BABA   87.26 (-5.14%)
NIO   15.71 (-5.53%)
AMD   96.02 (-6.29%)
CGC   5.60 (-4.92%)
MU   71.11 (-4.52%)
T   20.18 (-1.90%)
GE   75.23 (-1.53%)
F   12.75 (-5.76%)
DIS   104.39 (-3.91%)
AMC   12.72 (-1.40%)
PFE   50.28 (-2.06%)
PYPL   77.04 (-3.40%)
NFLX   177.26 (-6.98%)
S&P 500   3,916.23 (-4.22%)
DOW   31,419.51 (-3.78%)
QQQ   291.13 (-4.91%)
AAPL   140.68 (-5.74%)
MSFT   254.63 (-4.57%)
FB   193.11 (-4.69%)
GOOGL   2,255.52 (-3.17%)
AMZN   2,133.04 (-7.56%)
TSLA   706.71 (-7.21%)
NVDA   169.21 (-6.91%)
BABA   87.26 (-5.14%)
NIO   15.71 (-5.53%)
AMD   96.02 (-6.29%)
CGC   5.60 (-4.92%)
MU   71.11 (-4.52%)
T   20.18 (-1.90%)
GE   75.23 (-1.53%)
F   12.75 (-5.76%)
DIS   104.39 (-3.91%)
AMC   12.72 (-1.40%)
PFE   50.28 (-2.06%)
PYPL   77.04 (-3.40%)
NFLX   177.26 (-6.98%)
NASDAQ:AKTX

Akari Therapeutics (AKTX) Stock Forecast, Price & News

$1.14
+0.07 (+6.54%)
(As of 05/18/2022 02:48 PM ET)
Add
Compare
Today's Range
$1.10
$1.18
50-Day Range
$1.05
$1.24
52-Week Range
$1.00
$1.99
Volume
1,500 shs
Average Volume
48,598 shs
Market Capitalization
$67.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.24
30 days | 90 days | 365 days | Advanced Chart
Receive AKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Akari Therapeutics logo

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. Its lead product candidate is nomacopan, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Headlines

Akari Therapeutics net loss of $17.4M
Akari Therapeutics slips on $9M equity offering
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKTX
Employees
9
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.24 per share

Profitability

Net Income
$-17.08 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
22,671,000
Market Cap
$67.66 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/31/2020
Today
5/18/2022
Next Earnings (Estimated)
7/05/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.24 out of 5 stars

Medical Sector

1173rd out of 1,426 stocks

Pharmaceutical Preparations Industry

574th out of 680 stocks

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -













Akari Therapeutics (NASDAQ:AKTX) Frequently Asked Questions

When is Akari Therapeutics' next earnings date?

Akari Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, July 5th 2022.
View our earnings forecast for Akari Therapeutics
.

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics, Plc (NASDAQ:AKTX) released its quarterly earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.25.
View Akari Therapeutics' earnings history
.

Who are Akari Therapeutics' key executives?
Akari Therapeutics' management team includes the following people:
  • Dr. Ray Prudo-Chlebosz M.D., Exec. Chairman (Age 77, Pay $618k)
  • Dr. Torsten Hombeck, Chief Financial Officer (Age 52, Pay $309.86k)
  • Ms. Rachelle Suzanne Jacques, Pres, CEO & Director (Age 50)
  • Dr. Miles Nunn, Chief Scientific Officer
  • Annie Mack, Financial Controller
What other stocks do shareholders of Akari Therapeutics own?
What is Akari Therapeutics' stock symbol?

Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."

Who are Akari Therapeutics' major shareholders?

Akari Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Omnia Family Wealth LLC (1.28%), Hikari Power Ltd (0.22%) and Renaissance Technologies LLC (0.08%).
View institutional ownership trends for Akari Therapeutics
.

Which institutional investors are selling Akari Therapeutics stock?

AKTX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Akari Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Akari Therapeutics stock?

AKTX stock was bought by a variety of institutional investors in the last quarter, including Omnia Family Wealth LLC, and Hikari Power Ltd.
View insider buying and selling activity for Akari Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Akari Therapeutics?

Shares of AKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akari Therapeutics' stock price today?

One share of AKTX stock can currently be purchased for approximately $1.14.

How much money does Akari Therapeutics make?

Akari Therapeutics has a market capitalization of $67.66 million. The biopharmaceutical company earns $-17.08 million in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does Akari Therapeutics have?

Akari Therapeutics employs 9 workers across the globe.

What is Akari Therapeutics' official website?

The official website for Akari Therapeutics is www.akaritx.com.

How can I contact Akari Therapeutics?

Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The biopharmaceutical company can be reached via phone at 442080040261, via email at [email protected], or via fax at 646-843-9352.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.